New more sensitive diagnostics protect transplanted kidney
With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier,...
In this paper Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital and Chief Medical Officer at Devyser explains that, monitoring for mixed chimerism in patients after HSCT has in several studies been shown to be of
clinical importance. The main purpose of the assay is
to verify engraftment and subsequently monitor for
the presence of MRD and potentially early detection
of possible relapse.
With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier,...
Read More
Devyser, the pioneering leader in diagnostic solutions, launches today its first IVDR-certified...
Read More
“Further strong organic growth was reported for the year and quarter. Efforts to build an...
Read More
We are pleased to welcome Vertitas Corporation as a new distributor of the Devyser portfolio for...
Read More